Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma

Background: Regorafenib is a second-line therapy drug used for advanced hepatocellular carcinoma (HCC). Unfortunately, the survival benefit of the patients receiving this treatment is modest, which may be attributed to drug resistance. In the present study, sphingosine kinase 2 (SphK2) was targeted...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Weiwei Shi, Shan Zhang, Ding Ma, Dongliang Yan, Guang Zhang, Yin Cao, Zhongxia Wang, Junhua Wu, Chunping Jiang
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2020-06-01
Ráidu:	Frontiers in Oncology
Fáttát:	sphingosine kinase 2 sphingosine-1-phosphate ABC294640 regorafenib resistance hepatocellular carcinoma
Liŋkkat:	https://www.frontiersin.org/article/10.3389/fonc.2020.00694/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!